Revenue: As of FY2026 Q2, the actual value is USD 3.865 B, beating the estimate of USD 3.63 B.EPS: As of FY2026 Q2, the actual value is USD 0.34, beating the estimate of USD -0.033.EBIT: As of FY2026 Q2, the actual value is USD 127 M.<h3>Segmented Financial Metrics</h3><h4>Segment Revenue and Adjusted EBITDA</h4><ul><li>Americas Segment: For the three months ended March 31, 2026, net sales were $1,884 million, with Adjusted EBITDA of $109 million. Net sales increased by $185 million, or 11%, from $1,699 million in the prior year, driven by higher production volumes and favorable commercial pricing adjustments. For the six months ended March 31, 2026, net sales reached $3,526 million, with Adjusted EBITDA of $189 million. Net sales increased by $216 million, or 7%, from $3,310 million in the previous year due to similar factors .</li><li>EMEA Segment: For the three months ended March 31, 2026, net sales were $1,272 million, with Adjusted EBITDA of $45 million. Net sales increased by $41 million, or 3%, from $1,231 million in the prior year, primarily due to favorable foreign currencies, partially offset by lower production volumes. For the six months ended March 31, 2026, net sales were $2,477 million, with Adjusted EBITDA of $79 million. Net sales increased by $117 million, or 5%, from $2,360 million in the previous year, also attributed to foreign currency impacts despite lower production volumes .</li><li>Asia Segment: For the three months ended March 31, 2026, net sales were $734 million, with Adjusted EBITDA of $92 million. Net sales increased by $27 million, or 4%, from $707 million in the prior year, due to higher production volumes and favorable foreign currency impacts, partially offset by unfavorable commercial pricing adjustments. For the six months ended March 31, 2026, net sales were $1,553 million, with Adjusted EBITDA of $207 million. Net sales increased by $74 million, or 5%, from $1,479 million in the previous year, primarily due to higher production volumes and favorable foreign currency impacts .</li></ul><h4>Operational Metrics</h4><ul><li>Consolidated Gross Profit: For the three months ended March 31, 2026, gross profit was $257 million (6.6% of net sales), a decrease of -2% from $261 million (7.2% of net sales) in the prior year. For the six months ended March 31, 2026, gross profit was $474 million (6.3% of net sales), a -1% decrease from $477 million (6.7% of net sales) in the prior year .</li><li>Consolidated Selling, General and Administrative (SG&amp;A) Expenses: SG&amp;A decreased by $6 million, or -4%, to $138 million for the three months ended March 31, 2026, compared to $144 million in the prior year. For the six months ended March 31, 2026, SG&amp;A decreased by $1 million to $268 million compared to $269 million in the prior year .</li><li>Consolidated Restructuring and Impairment Costs: These costs were $5 million for the three months ended March 31, 2026, a -99% decrease from $351 million in the prior year. For the six months ended March 31, 2026, these costs were $29 million, a -92% decrease from $374 million in the prior year .</li><li>Consolidated Equity Income: Equity income decreased to $13 million for the three months ended March 31, 2026, from $18 million in the prior year. For the six months ended March 31, 2026, equity income decreased to $40 million from $43 million in the prior year .</li><li>Consolidated Net Financing Charges: These remained consistent at $48 million for the three months ended March 31, 2026, compared to the prior year. For the six months ended March 31, 2026, they increased by 3% to $96 million from $93 million in the prior year .</li><li>Consolidated Other Pension Expense: This expense increased to $3 million for the three months ended March 31, 2026, from $1 million in the prior year. For the six months ended March 31, 2026, it increased to $4 million from $2 million in the prior year .</li><li>Consolidated Income Tax Provision: The provision for income taxes was $32 million for the three months ended March 31, 2026, down -33% from $48 million in the prior year. For the six months ended March 31, 2026, it was $74 million, up 6% from $70 million in the prior year .</li><li>Consolidated Net Income (Loss) Attributable to Adient plc: Adient plc reported a net income of $27 million for the three months ended March 31, 2026, a significant improvement from a net loss of -$335 million in the prior year. For the six months ended March 31, 2026, net income was $5 million, a substantial improvement from a net loss of -$335 million in the prior year .</li></ul><h4>Cash Flow</h4><ul><li>Operating Activities: Cash provided by operating activities increased to $161 million for the six months ended March 31, 2026, from $64 million in the prior year .</li><li>Investing Activities: Cash used by investing activities increased to -$143 million for the six months ended March 31, 2026, from -$78 million in the prior year .</li><li>Financing Activities: Cash used by financing activities decreased to -$121 million for the six months ended March 31, 2026, from -$149 million in the prior year .</li></ul><h4>Capital Expenditures</h4><ul><li>Consolidated: Capital expenditures were $73 million for the three months ended March 31, 2026, and $138 million for the six months ended March 31, 2026, an increase from $45 million and $109 million for the respective periods in the prior year .</li><li>By Segment (6 months ended March 31, 2026): Americas ($63 million), EMEA ($49 million), Asia ($26 million) .</li></ul><h4>Working Capital</h4><ul><li>Working capital decreased by $69 million to $377 million as of March 31, 2026, from $446 million as of September 30, 2025 .</li></ul><h4>Debt and Financing Arrangements</h4><ul><li>Short-term debt: Adient plc had no short-term debt as of March 31, 2026, down from $2 million as of September 30, 2025 .</li><li>Long-term debt: Net long-term debt was $2,379 million as of March 31, 2026, a slight decrease from $2,386 million as of September 30, 2025 .</li><li>ABL Credit Facility: The maximum facility was reduced to $1,000 million, with $0 outstanding and $957 million availability as of March 31, 2026. The maturity date was extended to October 2030 .</li><li>Term Loan B Agreement: The outstanding balance was $622 million as of March 31, 2026. The applicable margin was reduced to 2.00%, and the maturity date was extended to January 2031 .</li></ul><h4>Unique Metrics</h4><ul><li>Capitalized Upfront Payments: Adient plc maintained capitalized upfront payments of $174 million as of March 31, 2026, unchanged from September 30, 2025 .</li><li>Investments in Partially-Owned Affiliates: Total investments were $301 million as of March 31, 2026, up from $276 million as of September 30, 2025, including a new $4 million investment in a Chinese joint venture in Q1 fiscal 2026 .</li></ul><h4>Future Outlook and Strategy</h4>Adient plc anticipates fiscal year 2026 cash flows to be lower than fiscal year 2025 due to reduced profitability, higher capital spending for growth, and non-recurring settlements from the prior year. The company is implementing a “2026 Plan” to reduce annual operating costs by approximately $15 million through workforce reductions in EMEA, aiming for completion by fiscal year 2027. Adient plc acknowledges a dynamic operating environment influenced by factors such as higher energy costs, softening consumer demand, and supply chain disruptions, which may negatively impact future results .

Adient | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 3.865 B